Clinical Trial Update: Efficacy of LCQ908 on Cardiovascular Risk [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating LCQ908 for cardiovascular risk in coronary artery disease and hypertriglyceridemia was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Hypertriglyceridemia

Drugs mentioned

• LCQ908

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Coronary Artery Disease, Hypertriglyceridemia | Phase 2 | Status: TERMINATED | Results posted: 2016-04-14